The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a delay to its review earlier this year.
Copyright © 2024 | WordPress Theme by MH Themes